Grey matter microglial imaging with [18F]DPA-714 in progressive MS patients - [18F]DPA-714 PET in MS

VU University Medical Center0 个研究点开始时间: 2014年12月1日最近更新: 2016年3月14日

适应症

试验速览

暂无简介。

•- For the MS patient group: diagnosis primary or secondary progressive MS with EDSS scores 4.0 to 7.5 - 18 to 60 years
•- Written informed consent
•- No immunomodulating or immunosuppressive treatment in previous three months
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 20
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•- Inability to undergo MRI, e.g. metal objects in or around the body, claustrophobia or inability to lie still in the scanner. For the MS patients: contra-indication for gadolinium administration, e.g. previous allergic reaction to gadolinium.
•- Homozygote Ala(147)Thr genotype (low-affinity binders)
•- Significant immune disease other than MS
•- (History of) other relevant neurological disease
•- History of malignancy
•- Known significant cardiac disease
•- Inadequate renal function: creatinine clearance <60 ml/min
•- Loss or donation of blood over 500 mL within four months prior to screening.
•- In male subjects Hb < 8.0 g/dL, in female subjects Hb < 7.0 g/dL
•- Pregnant or breast feeding
•- (History of) alcohol and/or drug abuse
•- Exposure to previous radiation leading to annual cumulative dose of more than 10 mSV if participating in this protocol
•- Use of benzodiazepines within 1 week of the PET scan

发起方

VU University Medical Center